Impact of 340B drug pricing program on specialty medication access: A policy analysis and future directions

The 340B Drug Pricing Program, initially designed to assist healthcare providers in offering affordable medications to vulnerable populations, has increasingly come under scrutiny, particularly concerning its impact on specialty medication access. This review critically examines the program’s effectiveness in improving access to high-cost specialty drugs, highlighting significant challenges such as program misalignment, economic pressures, and criticisms from the pharmaceutical industry. It further explores the regulatory landscape, stakeholder perspectives, and ethical considerations that shape the program’s implementation. The paper proposes reforms to refine eligibility criteria, enhance transparency, and adjust pricing structures to serve better patients needing specialty medications. Additionally, it discusses innovative strategies like digital health integration and industry partnerships that could enhance the program’s efficacy. The long-term implications of these proposed changes on healthcare systems, patients, and the pharmaceutical industry are considered, emphasizing the need for a balanced approach to sustain the 340B program’s mission in the evolving healthcare environment.